NPO Microgen, a part of Nacimbio holding company, was the first among the Russian manufacturers to confirm the stability of the vaccine virus strain and the quality of manufacturing of Russian-made tick-borne encephalitis vaccines at the gene level in accordance with WHO recommendations. Previously, no such molecular biological studies have been conducted for Russian-made tick-borne encephalitis vaccines.
The works began in 2012 and were implemented jointly with the experts of the Research Center for Expert Examination of Medicinal Products of the Russian Ministry of Health. They included the studies of biological and genetic stability of strain No. 205 (the Far Eastern subtype of the reference strain) of tick-borne encephalitis virus used to manufacture the inactivated tick-borne encephalitis vaccines, such as Encevir (for vaccination of adults) and Encevir Neo for Children (for vaccination of children).
Following the studies, Encevir and Encevir Neo were the first among Russian analogs to confirm the biological and genetic stability of the used strain of tick-borne encephalitis virus and, accordingly, the manufacturing process of medicines,” said Kirill Gaidash, acting General Director of NPO Microgen.
More than half a million people over 18 years old are vaccinated with Encevir in Russia each year. In 2016, this figure was 700 thousand people. In January 2015, NPO Microgen released Encevir Neo, a special version of the vaccine for prevention of tick-borne encephalitis in children from 3 to 17 years old.